Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal nicardipine for vasospasm after aneurysmal subarachnoid hemorrhage
ChiCTR2400084815Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nicardipine in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: Modified Rankin Scale score. Planned start May 2024; status: not yet recruiting.
02
Drugs
nicardipine
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on ChiCTR2400084815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084815.